Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Oculii | 2021 | Venture - Series Unknown | Undisclosed | Dayton |
| Matternet | 2026 | Debt Financing | $6.0M | Mountain View |
| CytoTronics | 2024 | Seed | $13.5M | Boston |
| Ripcord | 2024 | Series C | $32.0M | Hayward |
| ENSEM Therapeutics | 2023 | Series A | $10.0M | Medford |
| Merico | 2021 | Series A | Undisclosed | San Francisco |
| QL Biopharma | 2026 | Series C | $72.8M | Changping |
| Huihe Healthcare | 2025 | Series D | Undisclosed | Shanghai |
| LyncBio Therapeutics | 2025 | Seed | $14.3M | Shanghai |
| Ubot Robotics | 2025 | Series A | $14.1M | Shandong |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 1 | Oculii | Venture - Series Unknown | Undisclosed | Dayton, United States |
| 2 | Matternet | Debt Financing | $6.0M | Mountain View, United States |
| 3 | CytoTronics | Seed | $13.5M | Boston, United States |
| 4 | Ripcord | Series C | $32.0M | Hayward, United States |
| 5 | ENSEM Therapeutics | Series A | $10.0M | Medford, United States |
| 6 | Merico | Series A | Undisclosed | San Francisco, United States |
| 7 | QL Biopharma | Series C | $72.8M | Changping, China |
| 8 | Huihe Healthcare | Series D | Undisclosed | Shanghai, China |
| 9 | LyncBio Therapeutics | Seed | $14.3M | Shanghai, China |
| 10 | Ubot Robotics | Series A | $14.1M | Shandong, China |
Oculii develops AI Radar Perception Software that significantly enhances ADAS today and enables full autonomous driving in the future.
Matternet makes access to goods as frictionless and universal as access to information.
CytoTronics is designing and developing cell culture plates with embedded high-density electronic systems.
Ripcord is a digital transformation company that specializes in document management processes using robotics and AI.
ENSEM Therapeutics is a biotechnology company focusing on high value and difficult-to-drug oncology targets
Merico develops code analytics technology to support engineering teams in understanding and optimizing productivity and code quality.
QL Biopharma focuses on developing innovative drugs and premium me-too drugs targeting metabolic diseases.
Huihe Healthcare specializes in the development of medical devices for structural heart disease.
LyncBio Therapeutics is a medical company that provides treatments, research, and toxicology studies about intestinal inflammation.
Ubot Robotics is dedicated to developing leg-and-foot bionic robots.
Adaps Photonics is a manufacturer of high-performance photoelectric sensor chips.
New Cloud Medical is the leading pain specialist medical association
VelaVigo is a start-up company engaged in macromolecular biopharmaceutical.
Qingzhi is a Tianjin-based start-up developing autonomous driving technology for commercial vehicles.
ZSPepLib is a polypeptide drug developer.
X-ORIGIN-AI creates consumer-grade AI companion robots, redefining human-computer interaction with emotion-driven intelligence.
Axera is a hight-tech semiconductor company focused on developing world class Artificial intelligence (AI) SoCs for computer applications.
Reforgene Medicine is a biomedical company that uses gene editing and genomic technology to develop drugs intended to cure genetic diseases.
Healingovation is a med-tech company that specializes in the development of surgical robots, intelligent diagnosis and treatment equipment.
Arnatar Therapeutics is a biopharmaceutical company that specializes in the development of novel nucleic acid medications.
Carcell Biopharma is a pre-clinical biotech company that promotes the development of next-generation cell and gene therapies.
Carbon Energy Technology develops technology for carbon utilization and its commercialization.
Enjoy Move Technology is a solution provider of a safety software platform for the intelligent driving domain controller.
CoJourney is a CDMO platform for gene therapy that combines plasmid, viral vector, and mRNA generation, analysis, and detection.
Jixin Communication specialized in delivering core solutions for open communication chips.
Legend Star has invested in 92 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Legend Star's top investment sectors include Medical, Health Care, Manufacturing, Biotechnology, Artificial Intelligence (AI). The firm invests across 36 different industry categories.
Among tracked funding rounds, Axera received $136.1M in a Series C round. Legend Star's total known invested capital is $938.6M.
Legend Star's average investment size is $14.0M across its portfolio of 92 companies.
Recent Legend Star portfolio additions include Oculii, Matternet, CytoTronics, Ripcord, ENSEM Therapeutics. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors